Bristol Myers’ HCC Combo Drug Accepted for FDA Review – Bristol-Myers Squibb (NYSE:BMY)
Bristol Myers BMY introduced that the FDA has accepted its supplemental Biologics License Software (sBLA) for the immunotherapy drug, Opdivo ...
Tag: Bristol
Infographic: How Bristol Myers Squibb (BMY) performed in Q4 2023 financial results | AlphaStreet
Bristol Myers Squibb (NYSE: BMY) reported fourth quarter 2023 earnings outcomes immediately. Complete revenues inched up 1% to $11.5 billion ...
